Citius Pharmaceuticals Inc vs FirstEnergy Corp. — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $18.73M), while FirstEnergy Corp. trades at $46.86 (market cap $27.06B). The key difference: FirstEnergy Corp. is far larger — about 1444.7× Citius Pharmaceuticals Inc's market cap, and FirstEnergy Corp. pays a 3.98% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | FE | |
|---|---|---|
Market Cap | $18.73M | $27.06B |
Sector | Health | Utilities |
52-Week High | $1.82 | $51.91 |
52-Week Low | $0.48 | $42.83 |
Enterprise Value | $14.95M | $55.98B |
Dividend Yield | — | 3.98% |
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.68, up 6.28% today, with a bullish technical signal from moving averages. The company shows strong commercial momentum with LYMPHIR cancer treatment revenue reaching $5.6 million in H1 2026, though it remains unprofitable with a -823% net margin. Analyst consensus is strongly bullish with 83% buy ratings.
The outlook depends on LYMPHIR's commercial success offsetting deep losses. Near-term catalysts include expanded market access and combination therapy data, but high cash burn and execution risks require monitoring. The stock offers speculative growth potential in oncology but carries significant financial risk.
No Aura AI signal available yet.
Trailing returns across standard periods
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →FirstEnergy is one of the largest investor-owned utilities in the United States with 10 regulated distribution companies across six mid-Atlantic and Midwestern states. FirstEnergy also owns and operates one of the nation's largest electric transmission systems with 24,000 miles of lines.
Read more on FE →